Glaukos Corporation (GKOS) is a publicly traded Healthcare sector company. As of May 21, 2026, GKOS trades at $137.25 with a market cap of $8.35B and a P/E ratio of -44.00. GKOS moved -2.54% today. Year to date, GKOS is +27.83%; over the trailing twelve months it is +47.52%. Its 52-week range spans $73.16 to $163.71. Analyst consensus is strong buy with an average price target of $142.91. Rallies surfaces GKOS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Glaukos dips 3% as new 8-K investor deck sparks post-earnings profit-taking: Glaukos shares fell about 3% on May 4, 2026 after the company filed an 8-K furnishing an updated investor presentation. The move appears driven by post-earnings digestion and profit-taking following last week’s sharp rally after Q1 results and higher 2026 sales guidance.
| Metric | Value |
|---|---|
| Price | $137.25 |
| Market Cap | $8.35B |
| P/E Ratio | -44.00 |
| EPS | $-3.28 |
| Dividend Yield | 0.00% |
| 52-Week High | $163.71 |
| 52-Week Low | $73.16 |
| Volume | 22.73K |
| Avg Volume | 0 |
| Revenue (TTM) | $507.44M |
| Net Income | $-187.69M |
| Gross Margin | 55.72% |
12 analysts cover GKOS: 0 strong buy, 11 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $142.91.